Medication info
Glucophage XR 1000 mg Extended-Release Tablet (Metformin Hydrochloride)

Glucophage XR 1000 mg Extended-Release Tablet (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Merck
Appearance
Extended-release tablets that are oval-shaped, biconvex, and white to off-white.
Packaging
60 tablets (10 tablets/ PTP packaging X 6)
Approval status
Active

MFDS item code 201002150 · Approved 2010.03.18 · Insurance code 661700580

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - In patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin. - At initiation of treatment and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin in the blood should be measured approximately every 3 months. - The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment: - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this medicine must be discontinued immediately.

Ingredients

Importer
Merck

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for the treatment of adult patients with type 2 diabetes whose blood sugar control is insufficient with diet and exercise, particularly in those who are overweight. It can be taken alone or in conjunction with other oral hypoglycemic agents or insulin to help manage blood sugar effectively. This helps improve blood sugar levels and aids in the prevention of complications.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - In patients already receiving metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin. - At initiation of treatment and during dose adjustment, fasting blood glucose should be measured to assess the response to this medicine and determine the minimum effective dose. Glycated hemoglobin in the blood should be measured approximately every 3 months. - The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment: - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this medicine must be discontinued immediately.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis, which can be life-threatening. Additionally, when taken with insulin or other diabetes medications, there may be a risk of severe hypoglycemia, so caution is advised. Patients with moderate or higher renal impairment, dehydration, serious infections, or cardiovascular issues should not use this medication. Patients in acute conditions such as acute myocardial infarction or septicemia should avoid administration. Before and after tests using radiopaque iodine contrast agents, this medication should be temporarily discontinued and should not be reinstated until renal function is confirmed to be normal. Patients with hypersensitivity to this medication or certain conditions such as type 1 diabetes, diabetic ketoacidosis, severe infections, liver dysfunction, heart failure, etc., are prohibited from use. If undergoing surgery with restricted food and fluid intake, this medication should be stopped 48 hours prior to surgery, and should be resumed only after renal function has returned to normal. Caution is required for patients with poor nutritional status, weight loss, liver dysfunction, or excessive alcohol consumption. Vitamin B12 deficiency may occur during treatment with this medication, so regular blood tests are recommended. Gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.) are common and usually occur early in treatment but improve over time. Since this medication is excreted through the kidneys, regular kidney function monitoring is necessary, and if abnormalities occur, discontinue use. In patients with high physical activity or irregular eating habits, the risk of hypoglycemia or lactic acidosis may increase when taking this medication with others. During pregnancy, this drug can cross the placenta, so fetal growth should be monitored closely and treatment stopped if necessary. This medication is secreted in breast milk during lactation, thus the need for treatment should be carefully considered based on breastfeeding status. Elderly patients have a higher likelihood of renal function decline and should have their dosage adjusted and undergo regular kidney function tests. In case of overdose, lactic acidosis risk exists; medical attention should be sought immediately for treatment such as hemodialysis. Alcohol consumption during treatment with this medication is discouraged as it can increase the risk of lactic acidosis. For proper blood sugar control, regular monitoring of blood sugar and glycosylated hemoglobin levels is essential, and any unusual symptoms should be reported to healthcare professionals promptly. This medication should be swallowed whole and not chewed or crushed; the tablet shell may be eliminated in stool, which is normal. Finally, there are several medications that may interact with this one, so be sure to inform healthcare personnel about any other medications being taken and to take them carefully.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture, so it should be stored in a tightly closed container. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to safely preserve its efficacy.

Appearance and packaging

Appearance

Extended-release tablets that are oval-shaped, biconvex, and white to off-white.

Package unit

60 tablets (10 tablets/ PTP packaging X 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.